(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 2.83% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Charles River Laboratories International's revenue in 2023 is $4,215,776,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2023 to be $210,431,749,944, with the lowest CRL revenue forecast at $209,945,251,055, and the highest CRL revenue forecast at $210,845,766,449. On average, 6 Wall Street analysts forecast CRL's revenue for 2024 to be $218,524,282,446, with the lowest CRL revenue forecast at $216,567,668,451, and the highest CRL revenue forecast at $221,150,781,405.
In 2025, CRL is forecast to generate $237,180,314,500 in revenue, with the lowest revenue forecast at $234,384,689,978 and the highest revenue forecast at $240,053,653,679.